|Day Low/High||171.84 / 172.98|
|52 Wk Low/High||133.65 / 173.65|
Stop apologizing, don't surrender to the gloom and tell your story with sympathy but with glory, and don't make us feel like it's a mistake to own shares in your company.
Trading volumes dropping on major indexes, U.K. teams begin human trials on a Covid-19 vaccine, and the U.S. Senate wants another stimulus package addition.
Welcome to the new era. Social distancing is not without risks, but it is as good as it gets.
The rise in equity futures pricing was born of optimism from the president's task force draft guideline on reopening parts of the U.S. economy and Gilead Sciences' somewhat positive results on its remdisivir anti-viral treatment.
How has my book evolved since the Fed and Treasury rode into town? Here's how.
These companies have the potential to help in battling the Covid-19 pandemic.
When it's beaten you will wish you own stocks, especially the stocks that are right now lethal to your portfolio.
There is no joy in stockville -- instead we have big companies with stocks rising. Here's why that is and what you need to understand about the rally amid the crisis.
Earnings season started with a mixed bag of reports.
Long-time investors in JNJ are probably not surprised how well the stock has responded in the past few weeks.
There are plenty of good reasons to invest in JNJ, but one resonates with me more than any other.
I did warn publicly back in another epoch that quantitative easing would lead toward increased consumer level inflation.
In view of the obvious economic issues that the market faces, it is interesting that sentiment is not more negative.
I do think the key to reopening this economy is one of greatly expanded testing for Covid-19, once a reliable treatment has made it past clinical testing, and into mass production.
After a company reports we all know what's wrong, it's immunized. And that's when you can buy.
Now that the service economy is pretty much stopped in its tracks, here are promising areas, including technology as manufacturing, to consider.
I don't think it would be too much of a stretch to imagine that too many investors, or citizens for that matter, will mind seeing March 2020 head on out of here.
While Johnson & Johnson and other pharma cos. give us hope, here's my wish list to keep the nation safe and the economy ready to go again.
While the short-term picture of JNJ suggests more risk is possible, the longer-term patterns are constructive.
Japan is a leader in pharmaceuticals and has three companies working overtime to develop treatments for Covid-19.
These pharmaceutical names have what it takes amid the current crisis and for the long run.
A strong S&P for three days makes me leery of what's ahead, but here's an option in JNJ.
The Holy Grail right now are the few companies thriving and that will keep going after this is over, but there are others who will rebound and some who will not.
The healthcare giant's charts still show some signs of weakness but also indicate it could rally and make a base from a higher level.
JNJ should survive a recession and prove in demand in a health crisis.
In the 2nd of a 3-part series, Jim Cramer goes through all 30 Dow stocks to evaluate what is safe to buy and what you should sell or avoid (like the plague).
The company has grown organically and by acquisitions. It has dealt with adversity and bad news.
The answer to that question depends on several factors, so let's break them down.
For reliable income, a portfolio strategy generating monthly payouts, an opportunity in dividend kings, and favorites among taxable bond funds.